The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry

Abstract

Our specialized population-based registry has allowed us to explore changes in incidence and survival by subtype over the last 30 years. Between 1980 and 2009, 4790 cases of lymphoid malignancies were registered using the International Classification of Diseases for Oncology. The incidence rate of lymphoid malignancies was 20.5 per 100,000 inhabitants per year, and ranged from 0.1 to 4 according to subtype. Five-year net survival was 65%, and ranged from 41% to 93% according to subtype. We observed an increase in 5-year net survival between the periods 1980-1989 and 2000-2009 (58% vs. 70%). This was observed in most but not all subtypes. Our long-standing population-based registry allowed us to measure differences in trends according to the subtype of lymphoid malignancy. Incidence rates steadily increased in quite frequent entities, and poor survival probability for most entities indicates that they should be the next objective in therapeutic research programs.

Gender and ethnic differences in incidence and survival of lymphoid neoplasm subtypes in anAsian population: Secular trends of a population‐based cancer registry from 1998 to 2012

“…Our rates were, however, higher when compared to the West (11.6% during 1998–2012 vs . 5.4% in the US during 1992–2001, 1.5% in 1982–2004 during Australia, 6.0% in France during 1980–2009 and 3.8% in 44 European Cancer Registries during 2000–2002). Even within the same geographical location, our study had showed that there were ethnic differences in the ASIR of mature T/NK‐cell lymphoma, where the Malays had the lowest rates compared to the other ethnicities.…”

Association between abnormal serum free light chains ratio and known prognostic factors in lymphoma; a nephrology viewpoint

“…US Cancer Institute estimates the prevalence of non-Hodgkin’s and Hodgkin’s lymphomas to be 20.5 and 3 in every 100 000 people, respectively (2). Lymphoma is a cancer type with unknown risk factors and etiology.…”

A felnőttkori malignus hematológiai megbetegedések gyakorisága Szabolcs-Szatmár-Bereg megyében. 36 év adatainak elemzése

“…Az incidencia nehezen hasonlítható össze a külföldi adatokkal, amit már a 35 év adatait részletesen elemző munkánkban is hangsúlyoztunk [13]. Az ALL epidemiológiájával foglalkozó közlemények nagy többsége ugyanis a gyermek-és felnőttkori eseteket együtt tárgyalja, példa erre Dandoit és mtsai Franciaországnak egy megyénkkel csaknem azonos lélekszámú régiójában 30 év alatt regisztrált lymphoid malignitások incidenciájáról beszámoló közleménye [10]. Tovább nehezíti a helyzetet, hogy epidemiológiai elemzéseik során egyes szerzők, kö-zöttük Sant és mtsai, az ALL-t a "precursor lymphoblastic leukemia/lymphoma" betegcsoport részeként tárgyalják [3].…”

“…Néhány év adatait ismertető közleménnyel is csak elvétve találkozhatunk [3,4]. Még az egy-egy kiemelt entitás több évtizedre vonatkozó epidemiológiai jellemzőit taglaló közlemények sem gyakoriak [5][6][7][8][9][10][11].…”